Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Revance Therapeutics
(NQ:
RVNC
)
6.600
+0.010 (+0.15%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Revance Therapeutics
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
REVANCE THERAPEUTICS UPDATE
October 21, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Exposures
Product Safety
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Revance Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
October 21, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
REVANCE THERAPEUTICS SHAREHOLDER NOTICE
October 20, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Exposures
Product Safety
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Revance Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
October 20, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
12 Health Care Stocks Moving In Wednesday's Intraday Session
October 20, 2021
Gainers Sesen Bio (NASDAQ:SESN) stock increased by 29.2% to $1.3 during Wednesday's regular session. Trading volume for this security as of 12:30 EST is 149.3 million...
Via
Benzinga
REVANCE THERAPEUTICS SHAREHOLDER ALERT
October 19, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Exposures
Product Safety
46 Biggest Movers From Yesterday
October 19, 2021
Gainers Valneva SE (NASDAQ: VALN) shares surged 39.8% to close at $39.21 on Monday after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial...
Via
Benzinga
Lost Money in Revance Therapeutics, Inc.?
October 18, 2021
From
Gibbs Law Group
Via
Business Wire
REVANCE THERAPEUTICS INVESTOR ALERT
October 18, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Exposures
Product Safety
Mid-Afternoon Market Update: Dow Falls 70 Points; Evolving Systems Shares Spike Higher
October 18, 2021
Toward the end of trading Monday, the Dow traded down 0.20% to 35,223.86 while the NASDAQ rose 0.68% to 14,998.54. The S&P also rose, gaining 0.19% to 4,480.05. The U.S. has...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
October 18, 2021
Gainers Progenity (NASDAQ:PROG) shares increased by 33.17% to $2.85 during Monday's regular session. As of 12:30 EST, Progenity's stock is trading at a volume of...
Via
Benzinga
Revance Stock Loses 40% Of Its Value After FDA Rejects Its Frown Lines Injection
October 18, 2021
Revance Therapeutics tumbled Monday after the FDA rejected its frown lines injection.
Via
Investor's Business Daily
Exposures
Product Safety
Mid-Day Market Update: Nasdaq Rises 50 Points; Revance Therapeutics Shares Plummet
October 18, 2021
Midway through trading Monday, the Dow traded down 0.05% to 35,275.96 while the NASDAQ rose 0.34% to 14,948.46. The S&P also rose, gaining 0.19% to 4,479.71. The U.S. has the...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
34 Stocks Moving In Monday's Mid-Day Session
October 18, 2021
Gainers Valneva SE (NASDAQ: VALN) shares jumped 34.6% to $37.75 after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial Cov-Compare....
Via
Benzinga
Mid-Morning Market Update: Markets Mostly Lower; Albertsons Tops Q2 Estimates
October 18, 2021
Following the market opening Monday, the Dow traded down 0.32% to 35,182.99 while the NASDAQ rose 0.12% to 14,915.84. The S&P also fell, dropping 0.06% to 4,468.81. The U.S....
Via
Benzinga
Topics
Stocks
Exposures
US Equities
These 2 Nasdaq Biotechs Are Making Huge Premarket Moves Monday
October 18, 2021
The Nasdaq looks poised to open slightly lower after a strong week.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
10 Biggest Price Target Changes For Monday
October 18, 2021
Barclays reduced the price target for The Walt Disney Company (NYSE:
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
October 18, 2021
Gainers Valneva (NASDAQ:VALN) stock increased by 35.65% to $38.05 during Monday's pre-market session. The market value of their outstanding shares is at $1.8 billion....
Via
Benzinga
Why Revance Therapeutics Stock Is Getting Crushed Today
October 18, 2021
A surprise rejection is weighing on the biopharma's shares today.
Via
The Motley Fool
21 Stocks Moving in Monday's Pre-Market Session
October 18, 2021
Gainers Valneva SE (NASDAQ: VALN) rose 34.4% to $37.69 in pre-market trading after the company disclosed positive Phase 3 results for inactivated, adjuvanted COVID-19 vaccine...
Via
Benzinga
Exposures
COVID-19
Revance Shares Plunge On FDA Response Letter For Frown Line Candidate
October 18, 2021
The FDA has issued a Complete Response Letter (CRL) regarding Revance Therapeutics Inc's (NASDAQ: RVNC) marketing application for DaxibotulinumtoxinA for...
Via
Benzinga
Exposures
Product Safety
REVANCE ALERT: Bragar Eagel & Squire, P.C. is Investigating Revance Therapeutics, Inc. on Behalf of Revance Stockholders and Encourages Investors to Contact the Firm
October 15, 2021
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Revance Provides Regulatory Update on DaxibotulinumtoxinA for Injection for the Treatment of Moderate to Severe Glabellar (Frown) Lines
October 15, 2021
From
Revance Therapeutics, Inc.
Via
Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Revance Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
October 15, 2021
From
The Schall Law Firm
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Revance Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
October 14, 2021
From
The Schall Law Firm
Via
Business Wire
RVNC BREAKING NEWS: ROSEN, A TOP RANKED LAW FIRM, Encourages Revance Therapeutics, Inc. Investors with Losses to Inquire About Class Action Investigation – RVNC
October 14, 2021
From
Rosen Law Firm
Via
Business Wire
50 Biggest Movers From Yesterday
October 14, 2021
Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares surged 105.1% to close at $14.79 on Wednesday after Oppenheimer initiated coverage on the stock with an Outperform rating...
Via
Benzinga
40 Stocks Moving In Wednesday's Mid-Day Session
October 13, 2021
Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares jumped 113% to $15.36 after Oppenheimer initiated coverage on the stock with an Outperform rating and a $21 price target...
Via
Benzinga
Why Revance Therapeutics Stock Is Bolting Higher Today
October 13, 2021
Management's response to a publicly disclosed regulatory form has investors doing a U-turn.
Via
The Motley Fool
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
October 13, 2021
Gainers Revance Therapeutics (NASDAQ:RVNC) stock moved upwards by 17.79% to $24.09 during Wednesday's pre-market session. The company's market cap stands at $1.7...
Via
Benzinga
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.